As a leading and reliable service provider, Creative Biolabs is well known worldwide for its breakthrough in CAR production system. Based on targeting carcinoma-specific antigens in the follow table, our outstanding scientists have constructed diverse CAR T cells or CAR NK cells targeting these antigens. In addition to these, Creative Biolabs can also customize CAR product according to your special requirements.
Vicki Brower. The CAR T-Cell Race. The scientist. 2015
As a group of cancer, carcinoma usually starts from skin and spreads to other organs of the body. It accounts for 90% of all cancers, which mostly occurs in adults, with the DNA mutation as its main cause. Based on the tissue which cancer cells arise from, the primary carcinoma category includes breast cancer, prostate cancer, colorectal cancer, lung malignancy, adenocarcinomas, cervical carcinoma, melanoma and renal cell carcinoma. The most common symptom is lump under the skin, while there’re some other symptoms such as skin discolorations, pains. Although few strategies show effectiveness in carcinoma treatment, immunotherapy has performed great potential as a promising approach to treat carcinoma, such as CAR modified T cells or natural killer (NK) cells. Experts from Creative Biolabs can offer various CAR T cell or NK cells construction services according to your request.
Based on a great amount of experiments, we are confident our first-class CAR products can greatly accelerate your project process. Please feel free to contact us at any time.
Products against Carcinoma-specific antigens
|Associated malignancy||Target antigen||Receptor type||Product|
|Breast and others||erb-B2||ScFv-CD28mut-CD3ζ||Inquiry|
|erb-B2||ScFv-CD28-OX40-CD3ζ||pCDCAR1 ErbB2 h(28OXζ), T|
|erb-B 2,3,4||ScFv-CD3ζ||pCDCAR1 ErbB2 h(ζ), T|
|CEA||ScFv-CD28-CD3ζ||pCDCAR1 CEA h(28ζ), T|
|MUC1||ScFv-FcεRIγ||pCDCAR1 MUC1 h(γ), T|
|LeY||ScFv-CD3ξ||pCDCAR1 LeY h(ζ), T|
|Prostate cancer||erb-B2||ScFv-CD3ζ||pCDCAR1 ErbB2 h(ζ), T|
|PSCA||scFv-FcεRIγ||pCDCAR1 PSCA h(FcεRIγ), T|
|Colorectal cancer||CEA||ScFv-CD28-CD3ζ||pCDCAR1 CEA h(28ζ), T|
|EGP-40||ScFv-CD28-CD3ζ vs. CD3ζ||Inquiry|
|erb-B2||ScFV-CD28-FcεRIγ||pCDCAR1 ErbB2 h(28FcεRIγ), T|
|Lung malignancy||Her2/neu||ScFv-CD3ζ||pCDCAR1 ErbB2 h(ζ), T|
|Adenocarcinomas||TAG-72||ScFv-FcεRIγ (alloantigen)||pCDCAR1 TAG-72 h(γ), T|
|Melanoma||GD3||ScFv-CD3ζ||pCDCAR1 GD3 h(ζ), T|
|Renal cell carcinoma||CAIX||CD3 ζ /CD137/CD28||pCDCAR1 CAIX h(ζ), T|
|CAIX||CD3ζ(EBV)||pCDCAR1 CAIX h(ζ), T|
|Epithelial derived tumors||LeY||ScFv-CD3ξ||pCDCAR1 LeY h(ζ), T|
Copyright © 2007 - 2017 Creative Biolabs. All Rights Reserved